The revenue figures, disclosed by partner Eisai alongside Biogen’s quarterly report, highlight the commercial momentum of the monoclonal antibody. While the second quarter of 2025 included a 5.3 billion yen windfall from stockpiling in the Chinese market, the current period demonstrates organic expansion in the drug's global footprint. BioArctic, which holds the rights to the treatment it co-developed with Eisai, continues to benefit from these global sales milestones without bearing ongoing development costs for the Alzheimer’s indication.

Leqembi is currently approved in 53 countries, with recent regulatory progress including subcutaneous dosing approvals and inclusion in China’s commercial insurance lists. BioArctic is scheduled to release its full financial report on August 26, 2026, which will provide a deeper look at the company’s broader research portfolio, including ongoing work in Parkinson’s and ALS treatments.